Full-Time

Finance Associate

Confirmed live in the last 24 hours

Insulet Corporation

Insulet Corporation

1,001-5,000 employees

Develops tubeless insulin delivery systems

No salary listed

Entry, Junior

Sydney NSW, Australia

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
SAP Products
Excel/Numbers/Sheets
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Insulet Corporation referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Strong analytical, problem-solving skills and ability to work independently.
  • Strong knowledge of Excel and ability to work with different IT systems
  • Ability to quickly build rapport and establish trust with others by effective listening and gaining insights by asking appropriate questions.
  • Ability to express oneself clearly in conversations and interactions.
  • Ability to express oneself clearly in business writing.
  • Ability to ensure one's own and others' work and information are complete and accurate.
  • Ability to function effectively in a fast-paced environment. Can handle several problems or tasks at once through effective time management and multi-tasking. Ability to maintain flexibility, and able to switch priorities as needed based on business needs.
  • Knowledge of medical device reimbursement from manufacturer or DME perspective
  • Knowledge of Accounts Payable, Account Receivable, and accounting reconciliations.
  • Experience in accounts receivables reconciliation
  • Understanding and experience with Private health insurance claims and reimbursement
  • Understanding of direct to consumer payments and ability to do cash book reconciliation between payments and invoices.
Responsibilities
  • Responsible of the weekly reconciliation of all customer subscription payments, making sure invoices are generated, and payments allocated correctly by the AR team.
  • Trouble shoot any issues with private health fund invoices and payments.
  • Weekly investigate SAP billing blocks and working the Commercial Operations Associate that all training records are completed.
  • Provide support to the AR team with any escalation issues.
  • Provide backup for indirect purchasing from purchase requisition through to payment, including supplier creation.
  • Do monthly opex accruals.
  • Assist with Actuals vs budget Opex reporting.
  • Provide backup for monthly NDSS validation, and invoicing.
  • Provide support to the Customer Operations Lead for controls to support manual process checking, ie billing blocks, PHI invoices sent, and subscription orders approved.
  • Work as part of the larger support team, collaborating with other departments to ensure proactive, superior administrative support.
  • Provide frequent feedback and suggestions to support an environment of continuous process improvement.
  • Perform other duties as assigned.
Desired Qualifications
  • Knowledge of medical device reimbursement from manufacturer or DME perspective (preferred)
  • Salesforce CRM System experience (preferred)

Insulet Corporation develops medical devices aimed at simplifying life for people with diabetes. Their main product, the Omnipod Insulin Management System, is a tubeless device that delivers insulin continuously for up to three days without needles. The Omnipod 5 Automated Insulin Delivery System integrates with a continuous glucose monitor, allowing users to manage blood sugar without multiple injections or fingersticks. Insulet differentiates itself by providing a user-friendly solution that enhances insulin management, with the goal of improving the quality of life for individuals with diabetes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for advanced diabetes solutions expands Insulet's market opportunities.
  • Omnipod 5's European expansion increases Insulet's international market presence.
  • Advancements in sensor technology enhance the reliability of Insulet's Omnipod system.

What critics are saying

  • Leadership transition to Ashley McEvoy may lead to strategic instability.
  • Increased competition from DexCom and Tandem Diabetes Care challenges Insulet's market share.
  • Potential financial strain from $450M senior notes offering could impact cash flow.

What makes Insulet Corporation unique

  • Insulet's Omnipod 5 integrates with Dexcom G7 CGM, enhancing diabetes management.
  • The RADIANT trial showcases Insulet's innovation in transitioning from daily injections to Omnipod.
  • Insulet's $452M trade secret victory strengthens its competitive position in insulin pump technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
RTTNews
Apr 28th, 2025
Insulet CEO Jim Hollingshead Resigns, Ashley McEvoy To Succeed; Raises Q1 Guidance

Insulet Corp. (PODD), a medical device company, on Monday announced that Chief Executive Officer Jim Hollingshead has resigned from the Board of Directors.

MD+DI
Apr 28th, 2025
Insulet Names Ex-J&J MedTech Chief Ashley McEvoy as CEO

Ashley McEvoy has been tapped to be president and CEO of Insulet.

Financial Modeling Prep
Mar 28th, 2025
Insulet Corporation's Financial Efficiency in the Medical Device Industry

Insulet competes with companies like DexCom, Tandem Diabetes Care, and Masimo Corporation in the diabetes care market.

Stock Titan
Mar 18th, 2025
Insulet Secures $450M Through Senior Notes Offering: Key Details on Strategic Debt Refinancing

Insulet raises $444.4M through senior notes to refinance existing convertible debt. Strategic move positions medical device maker for future growth while optimizing capital structure.

Stock Titan
Mar 18th, 2025
From Injections to Innovation - Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod(R) 5 in Adults and Children with Type 1 Diabetes

Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025.